The placebo response in clinical trials for rheumatoid arthritis appears to have grown over the last two decades with patients exhibiting significant improvements in pain scores with placebo treatment.
In this slideshow, we feature results from some noteworthy rheumatoid arthritis studies that were recently published: improved patient-reported outcomes in refractory rheumatoid arthritis with use of a JAK inhibitor, mortality risk with coronary microvascular dysfunction similar in rheumatoid arthritis and diabetes, prescriber preference affects the length of time a patient takes a conventional synthetic DMARD before switching to a biologic DMARD, and more.
The JAK inhibitor upadacitinib was approved last August for the treatment of moderate to severe rheumatoid arthritis. In this quiz, we focus on findings from a recent phase three clinical trial that tested different doses of this new oral medication. Test your knowledge of upadacitinib in this quiz.
How strong is the familial link in rheumatoid arthritis? The answer may surprise you. Test your knowledge in this quiz.
Treatment with the recently approved oral, selective JAK-1 inhibitor upadacitinib (Rinvoq, AbbVie) resulted in significant improvements in various patient-reported outcomes among individuals with rheumatoid arthritis who have had inadequate responses to biologic DMARDs, researchers report in Arthritis Research & Therapy.
Psoriatic arthritis patients with moderate disease activity were more likely to reach treatment targets or low disease activity at week 52 with apremilast (Otezla, Celgene) than patients with high disease activity, researchers report in the January 7 issue of Arthritis Care and Research.
Patients and doctors still haven't fully invested in the use of biosimilars, despite a steady rise in the cost of biologics, shows a new report by Harvard researchers.
Turkish researchers are reporting the results of small study that shows too much vitamin D may be associated with the severity of in disease ankylosing spondylitis patients. Learn more about this and other recent findings from spondylarthritis research in today's news roundup.
Updated treatment guidelines for hand, hip and knee osteoarthritis have been issued. In this slideshow, we highlight recommendations for the use (or not) of drug and nondrug treatments. These include strong recommendations for standard treatment options, such as weight loss and Tai Chi, and strong recommendations against treatments with pharmacologicals, such as glucosamine and chondroitin sulfate (except for hand osteoarthritis). Learn more in this slideshow.
The American College of Rheumatology (ACR), in partnership with the Arthritis Foundation, has issued treatment guidelines for osteoarthritis of the hand, hip and knee. This is the first update since 2012.